Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02965573 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of ARGX-113 in Patients With Myasthenia Gravis Who Have Generalized Muscle Weakness
A Phase 2 study of Myasthenia Gravis, sponsored by argenx.
- Completed
- Registry status
- Phase 2
- Development phase
- 24
- Enrollment target
- 19
- Study locations
NCT02965573 is a Phase 2 study of Myasthenia Gravis that has completed, run by argenx. The registered enrollment target is 24 participants, below the 190-participant average among 32 other Myasthenia Gravis trials with a reported enrollment target (87% lower). The trial reports 19 study locations across 6 states.
The verdict
NCT02965573, a Phase 2 study of Myasthenia Gravis, has completed, sponsored by argenx.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 24 participants
- Enrollment target
- 19
- Study locations
Study Summary
This is a randomized, double-blind, placebo-controlled, multicenter Phase II study to evaluate the safety, efficacy, and pharmacokinetics of ARGX-113 for the treatment of autoimmune Myasthenia Gravis (MG) with generalized muscle weakness.
Conditions Studied
Interventions
- DRUG Placebo
- BIOLOGICAL ARGX-113
Study Locations (19)
Other
- Investigator Site 2 - Ghent
- Investigator Site 1 - Leuven
- Investigator Site 4 - Montreal
- Investigator Site 3 - Toronto
- Investigator Site 7 - Bergamo
- Investigator Site 6 - Milan
- Investigator Site 5 - Roma
- Investigator Site 8 - Leiden
- Investigator Site 10 - Gdansk
- Investigator Site 9 - Krakow
- Investigator Site 12 - Barcelona
- Investigator Site 11 - Madrid
- Investigator Site 13 - Solna
California
- Investigator Site 19 - Irvine
- Investigator Site 17 - Los Angeles
Florida
- Investigator Site 15 - Tampa
Indiana
- Investigator Site 16 - Indianapolis
North Carolina
- Investigator Site 14 - Chapel Hill
Ohio
- Investigator Site 18 - Dublin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2016-12-30 |
| Est. Completion | 2017-10-20 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02965573
The ClinicalTrials.gov registry entry for NCT02965573 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 190-participant average among 32 other Myasthenia Gravis trials with a reported enrollment target (87% lower). The listed sponsor is argenx, which has 49 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Myasthenia Gravis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT02965573 reports 19 study locations spanning 6 distinct geographic areas - top geographies include Other, California, Florida.
Frequently Asked Questions
What is clinical trial NCT02965573 about?
NCT02965573 is a clinical study titled "A Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of ARGX-113 in Patients With Myasthenia Gravis Who Have Generalized Muscle Weakness". This is a randomized, double-blind, placebo-controlled, multicenter Phase II study to evaluate the safety, efficacy, and pharmacokinetics of ARGX-113 for the treatment of autoimmune Myasthenia Gravis (MG) with generalized muscle weakness.
What is the current status of trial NCT02965573?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 24 participants. The study started on 2016-12-30. Estimated completion is 2017-10-20.
What conditions does trial NCT02965573 study?
This clinical trial studies the following conditions: Myasthenia Gravis.
What interventions are being tested in trial NCT02965573?
The interventions under investigation include: Placebo (DRUG), ARGX-113 (BIOLOGICAL).
Who is sponsoring clinical trial NCT02965573?
This trial is sponsored by argenx, which has 49 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02965573 being conducted?
This trial has 19 study locations across California, Florida, Indiana, North Carolina, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Myasthenia Gravis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
KYSA-6: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, in Patients With Generalized Myasthenia Gravis
RECRUITING · Phase 2
-
ADAPT Forward 1 - ISA1 - a Study to Evaluate Empasiprubart IV as add-on Therapy to Efgartigimod IV in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis With a Partial Clinical Response to Efgartigimod
RECRUITING · Phase 2
-
Safety and Efficacy of 3 Dose Levels of NMD670 in Adult Patients With Myasthenia Gravis
RECRUITING · Phase 2
-
A Study of Nipocalimab in Children Aged 2 to Less Than 18 Years With Generalized Myasthenia Gravis
RECRUITING · Phase 2
-
BeatMG: Phase II Trial of Rituximab In Myasthenia Gravis
COMPLETED · Phase 2
-
A Study of RVT-1401 in Myasthenia Gravis (MG) Patients
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.